Immunotherapy with BCG administered by scarification. Standardization of reactions and management of side effects (Q39780012)

14 September 2017

1 reference

title

Immunotherapy with BCG administered by scarification: standardization of reactions and management of side effects (English)

1 reference

14 September 2017

Immunotherapy with BCG administered by scarification. Standardization of reactions and management of side effects (English)

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

8 April 2023

1 reference

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

8 April 2023

author name string

G. N. Hortobagyi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363257

8 April 2023

S. P. Richman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363257

8 April 2023

K. Dandridge

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363257

8 April 2023

J. U. Gutterman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363257

8 April 2023

G. R. Blumenschein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363257

8 April 2023

E. M. Hersh

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A363257

8 April 2023

language of work or name

English

0 references

publication date

1 November 1978

1 reference

full work available at URL

14 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

8 April 2023

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

8 April 2023

1 reference

14 September 2017

volume

42

1 reference

14 September 2017

issue

5

1 reference

14 September 2017

page(s)

2293-2303

1 reference

Immunotherapy for acute myelogenous leukaemia

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197811%2942%3A5%3C2293%3A%3AAID-CNCR2820420529%3E3.0.CO%3B2-O

Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3

21 January 2018

2

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

BCG and cancer (first of two parts).

8 April 2023

3

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Immunological Effects of BCG in Malignant Melanoma: Two Modes of Administration Compared

8 April 2023

6

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 34-1975

8 April 2023

8

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Suppression of lymphocyte transformation after aspirin ingestion

8 April 2023

11

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

A new apparatus for BCG scarification

8 April 2023

12

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

The Current Status of BCG Immunization Against Tuberculosis

8 April 2023

13

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.

8 April 2023

16

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Cancer Immunology, Immunotherapy

8 April 2023

17

1

99

Gutterman

1976

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Chemoimmunotherapy of Disseminated Malignant Melanoma with Dimethyl Triazeno Imidazole Carboxamide and Bacillus Calmette-Guérin

8 April 2023

19

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Chemoimmunotherapy of human solid tumors

8 April 2023

20

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Active immunotherapy with B.C.G. for recurrent malignant melanoma

8 April 2023

22

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G.

8 April 2023

24

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Immunopotentiation With BeG. I. Immune Response to Different Strains and Preparations2

8 April 2023

31

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Failure of BCG immunostimulation to affect the clinical course of Burkitt's lymphoma

8 April 2023

32

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

8 April 2023

Active immunotherapy

34

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Immunotherapy: its possible application in the management of large-bowel cancer.

8 April 2023

35

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Immunotherapy of melanoma with BCG: Two fatalities following intralesional injection

8 April 2023

37

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Regional immunotherapy of lung cancer with intrapleural B.C.G

8 April 2023

38

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Intrapleural B.C.G. immunostimulation in lung cancer

8 April 2023

39

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

BCG immunotherapy of malignant melanoma: summary of a seven-year experience

8 April 2023

40

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma

8 April 2023

41

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Immunological monitoring and immunotherapy in carcinoma of the lung

8 April 2023

45

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

GENERALIZED BCG INFECTION

8 April 2023

46

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

A 5-year controlled study of B.C.G. and radiotherapy inoperable lung cancer

8 April 2023

47

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Disseminated bcg disease associated with immunotherapy by scarification in acute leukemia

8 April 2023

51

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG

8 April 2023

52

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Systemic infection following BCG therapy

8 April 2023

53

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Delay in Progression of Malignant Lymphoma after BCG Vaccination

8 April 2023

54

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Hazards and Complications of BCG Immunotherapy

8 April 2023

55

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Complications of BCG immunotherapy in patients with cancer

8 April 2023

56

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Skeletal and soft tissue sarcomas. Treatment with adjuvant immunotherapy

8 April 2023

57

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

Immunotherapy with chemotherapy in the maintenance of remission in acute myeloblastic leukaemia

8 April 2023

58

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

8 April 2023

60

35

1779

Yron

1975

1 reference

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

https://api.crossref.org/works/10.1002/1097-0142(197811)42:5%3C2293::AID-CNCR2820420529%3E3.0.CO;2-O

8 April 2023

Identifiers

10.1002/1097-0142(197811)42:5<2293::AID-CNCR2820420529>3.0.CO;2-O

1 reference

14 September 2017

1 reference